India, May 26 -- Global pharmaceutical major Lupin Limited has announced a strategic license and supply agreement with SteinCares, a prominent specialty healthcare company in Latin America, for the commercialization of its biosimilar Ranibizumab across the region—excluding Mexico and Argentina.
Under the agreement, SteinCares will be responsible for regulatory filings, product registration, and marketing of Ranibizumab in Latin American markets, while Lupin will oversee the manufacturing of the drug.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is indicated for several serious retinal conditions, including Neovascular (Wet) Age-Re...